Press releases

and Washington, D.C. (September 29, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced two-year follow-up data from its TAXUS II paclitaxel-eluting stent system clinical trial. The...

(September 28, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it will make a special one-time contribution to the Company's U.S. 401(k) Retirement Savings Plan. All...

(September 24, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that its subsidiary, Advanced Bionics Corporation of Sylmar, California, is voluntarily recalling worldwide all...

(September 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events at the Transcatheter Cardiovascular Therapeutics (TCT) conference in...

(September 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has completed its inspection of the Company's Galway, Ireland...

(September 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) today provided an update on the sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for the month of August...

(August 31, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced six-month clinical findings from the European component of its Milestone II Registry. The Company said it has...

(August 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that enrollment has begun in its ATLAS clinical trial. ATLAS is the first trial using Boston Scientific's new Liberté™

(August 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast a conference call providing updates on its business performance for 2004 and sales of its TAXUS™ Express2™...

(August 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its Peripheral Cutting...